


Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Use as many sheets as necessary)</small>		<small>Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.</small>	
		Complete if Known	
		Application Number	10/723,423
		Filing Date	November 26, 2003
		First Named Inventor	Jensen, Gerard
		Group Art Unit	1615
		Examiner Name	Unknown
Sheet 1 of 2		Attorney Docket No: 1992.005US1	

US PATENT DOCUMENTS				
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
W	US-4,145,410	03/20/1979	Sears, Barry D.	06/17/1997
	US-4,224,179	09/23/1980	Schneider, Michel	09/23/1980
	US-4,235,871	11/25/1980	Papahadjopoulos, Demetrios P., et al.	02/24/1978
	US-4,522,803	06/11/1985	Lenk, Robert P., et al.	03/24/1983
	US-4,588,578	05/13/1986	Fountain, Michael W., et al.	08/08/1983
	US-4,753,788	06/28/1988	Gamble, Ronald C.	01/31/1985
	US-4,946,683	08/07/1990	Forssen, Eric A.	08/04/1989
W	US-5,077,056	12/31/1991	Bally, M. B., et al.	12/12/1988
	US-5,316,771	05/31/1994	Barenholz, Yechezkel , et al.	12/18/1992
	US-5,380,531	01/10/1995	Chakrabarti, Ajoy , et al.	06/02/1992
	US-5,795,589	08/18/1998	Mayer, Lawrence D., et al.	02/05/1997
W	US-5,814,335	09/29/1998	Webb, Murray S., et al.	09/17/1997
	US-6,083,530	07/04/2000	Mayer, Lawrence D., et al.	05/26/1998

FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T ²
W	EP-0546951A1	06/16/1993	Ostro, Marc J.	
	EP-0719546A1	07/03/1996	Bally, Marcel B., et al.	
W	WO-03041682A3	05/22/2003	Webb, Murray , et al.	
W	WO-9913816A2	03/25/1999	Moynihan, Karen L., et al.	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
W		ADLAKHA-HUTCHEON, G. , et al., "Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity", <i>Nature Biotechnology</i> , 17(8), (August 1999),775-779		
		BANDAK, S. , et al., "Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models", <i>Anticancer Drugs</i> , 10, (November 10, 1999),911-920		
		COLBERN, C. T., et al., "Antitumor activity of Herceptin in combination with STEALTH liposomal cisplatin or nonliposomal cisplatin in a HER2 positive human breast cancer model", <i>Journal of Inorganic Biochemistry</i> , 77(1-2), (October 1999),117-120		
W		DEMARIO, M. D., et al., "A Phase I Study of Liposome-Formulated Cisplatin (SPI-77 R) Given Every 3 Weeks in Patients With Advanced Cancer", <i>Proceedings of ASCO</i> , Vol. 17, http://www.asco.org/ac/1,1003,_12-002643-00_18-0031-00_19-006314,00.asp,(1998),Abstract 883		

EXAMINER *Kris* DATE CONSIDERED *3/7/07*

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Use as many sheets as necessary)</small>		Complete if Known Application Number 10/723,423 Filing Date November 26, 2003 First Named Inventor Jensen, Gerard Group Art Unit 1615 Examiner Name Unknown	
Sheet 2 of 2		Attorney Docket No: 1992.005US1	

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>lw</i>		HARRINGTON, K. J., et al., "Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer", <u>Annals of Oncology</u> , 12(4), (April 2001), 493-496	
<i>lw</i>		HONG, R L., et al., "Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice is surface coating with polyethylene glycol beneficial?", <u>Clinical Cancer Research</u> , 5(11), (November 1999), 3645-3652	
<i>lw</i>		LIM, H. J., et al., "Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone", <u>The Journal of Pharmacology and Experimental Therapeutics</u> , 281(1), (April 1997), 566-573	
<i>lw</i>		MEERUM TERWOGT, J. M., et al., "Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin", <u>Cancer Chemotherapy and Pharmacology</u> , 49(3), (March 2002), 201-210	
<i>lw</i>		NEWMAN, M. S., et al., "Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice", <u>Cancer Chemotherapy and Pharmacology</u> , 43(1), Erratum in <u>Cancer Chemotherapy and Pharmacology</u> , 43(6), 524 (attached to downloaded document), (1999), 1-7	
<i>lw</i>		VEAL, G. J., et al., "A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin", <u>British Journal of Cancer</u> , 84(8), (April 2001), 1029-1035	
<i>lw</i>		WORKING, P. K., et al., "Comparative intravenous toxicity of cisplatin solution and cisplatin encapsulated in long-circulating, pegylated liposomes in cynomolgus monkeys", <u>Toxicological Sciences</u> , 46(1), (November 1998), 155-165	

EXAMINER

Kirke

DATE CONSIDERED

3/7/07



PTO-50-13A(03)

Approved for use through 10/31/2003 GPO 0-19-0300
U.S. Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449A/PTO
INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use as many sheets as necessary)

Complete if Known

		Application Number	10/723,423
		Filing Date	November 26, 2003
		First Named Inventor	Jensen, Gerard
		Group Art Unit	1615
		Examiner Name	Unknown
Sheet 1 of 1		Attorney Docket No: 1992.005US1	

US PATENT DOCUMENTS

Examiner Initials*	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
ha	US-3,993,754	11/23/1976	Rahman, Yueh-Erh , et al.	514	12	10/09/1974
	US-4,885,172	12/05/1989	Bally, M. B., et al.	424	417	12/15/1986
	US-4,938,949	07/03/1990	Borch, Richard F., et al.	514	476	09/12/1988
lm	US-5,616,341	04/01/1997	Mayer, L. D., et al.	424	450	08/26/1993

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ²
ha	EP-0290296A2	11/09/1988	Bally, M. B., et al.	A61K	9/50	
	WO-0105372A2	01/25/2001	Abra, R. M., et al.	A61K	9/00	
	WO-8601102A1	02/27/1986	Bally, Marcel B., et al.	A61K	9/60	
ha	WO-9202244A1	02/20/1992	Chakrabarti, A. , et al.	A61K	37/22	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²

EXAMINER

Kush

DATE CONSIDERED

3/7/07

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Indicate if reference considered, whether or not citation is in conformance with 35 U.S.C. § 141. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) if Applicant is to place a check mark here if English language Translation is attached.